> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GSK Nixes Herpes Simplex Virus Vaccine
- URL: https://www.fdaweb.com/gsk-nixes-herpes-simplex-virus-vaccine/
- Published: 2024-09-11T12:00:00.000Z
- Updated: 2026-09-14T14:40:54.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5157758

GSK is not advancing the development of its investigational herpes simplex virus (HSV) vaccine candidate, GSK3943104, based on a data analysis of a recent Phase 1-2 study. “Results show that GSK3943104 did not meet the study’s primary efficacy objective,” the company says, adding that it will not progress to Phase 3 studies.

GSK notes that no safety concerns were observed in the study, which will continue for “routine safety monitoring and to generate follow-up data that could offer valuable insights into recurrent genital herpes… GSK intends to evaluate the totality of all these data and other studies to progress future research and development of its HSV program.”